FDA Peptide Approvals and Guidance: Signals for the Regulatory Path of Peptide Therapeutics
Peptide therapeutics occupy a structurally distinct regulatory space — synthesized as small molecules yet carrying complexity that invites biologic-style scrutiny. For regulatory and clinical development teams, understanding how FDA is treating this class is not merely academic: pathway selection, manufacturing expectations, and clinical pharmacology requirements each carry material consequences for timelines and resource planning.
The analysis below surveys recent NDA approvals across therapeutic areas, the established 505(j) generic route for synthetic peptides, and FDA's evolving guidance on immunogenicity, aggregation, and pharmacokinetic characterization — mapping what these signals collectively mean for sponsors developing peptide drug candidates.
Want to ask Rhizome your own regulatory questions? Try it for free.
What recent FDA peptide approvals and guidance signal about the regulatory path for peptide therapeutics
Peptides now sit in an unusual regulatory position. They are chemically synthesized and, like small molecules, are reviewed by CDER under new drug applications (NDAs) rather than as biologics, yet they carry biologic-like risks such as immunogenicity and aggregation. Recent FDA approvals and a cluster of peptide-specific guidance documents show the agency converging on a coherent framework: the NDA remains the primary original pathway, a defined 505(j) generic route exists for certain synthetic peptides, and clinical pharmacology expectations are being tailored to peptide-specific biology rather than imported wholesale from either small molecules or biologics.
The approval pattern: NDAs across metabolic, rare, and imaging indications
Recent peptide approvals have all come through the NDA route, spanning metabolic disease, rare/orphan indications, and radiodiagnostics. This breadth matters for strategy: peptides are not confined to one therapeutic niche or one review division.
| Product | Active ingredient | Application | Approval | Review track / designations | Indication |
|---|---|---|---|---|---|
| Wegovy | semaglutide | NDA | 2021-06-04 187 | — | Chronic weight management in adults with obesity or overweight plus a comorbidity 187 |
| Mounjaro | tirzepatide | NDA 215866 | 2022-05-13 88102 | Priority review; priority review voucher; Emerging Technology Program 808288104 | Glycemic control in type 2 diabetes 17 |
| Terlivaz | terlipressin acetate | NDA 022231 | 2022-09-14 110113 | Priority review; orphan drug; fast track 110111117 | Hepatorenal syndrome, type 1 5 |
| Posluma | flotufolastat F-18 | NDA | 2023-05-25 185 | — | PSMA-targeted PET imaging in prostate cancer 185 |
| Aphexda | motixafortide acetate | NDA 217159 | 2023-09-08 206210 | Standard review; orphan drug (2012) 210212 | With G-CSF to mobilize hematopoietic stem cells for autologous transplant in multiple myeloma 210 |
| Zepbound | tirzepatide | NDA | 2023-11-08 201 | — | Weight management in adults 201 |
Two signals stand out. First, expedited tools are fully available to peptides: Terlivaz combined priority review with both orphan drug and fast track designation 110111117, and Mounjaro cleared on an eight-month priority clock supported by a priority review voucher and participation in FDA's Emerging Technology Program for its manufacturing 8082104. Second, the metabolic incretin peptides (semaglutide, tirzepatide) show the now-familiar pattern of a first NDA in one indication followed by a separate NDA and brand for a second indication (Mounjaro/Zepbound for tirzepatide; Wegovy alongside the diabetes franchise for semaglutide) 17201187, reinforcing that indication expansion for peptides is handled through the standard NDA/supplement machinery rather than any peptide-specific track.
A defined generic pathway for synthetic peptides
The most consequential lifecycle signal is FDA's finalized position that certain synthetic peptides can be approved as generics under an ANDA. The final guidance, ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin (2021-05-19), applies to five specific peptides whose reference listed drugs were originally made by recombinant DNA technology: glucagon, liraglutide, nesiritide, teriparatide, and teduglutide 42.
The guidance sets a demanding "sameness" bar. An applicant must demonstrate the proposed synthetic peptide is the same as the RLD active ingredient through physicochemical characterization and biological evaluation, comparing primary sequence, physicochemical properties, secondary structure, oligomer/aggregation state, and biological activity 384143. The impurity criteria are the operative constraint: any peptide-related impurity shared with the RLD should be at or below the RLD level; no new specified peptide-related impurity should exceed 0.5% of the drug substance; and each new specified impurity at or below 0.5% must be characterized and justified as not affecting safety or effectiveness, explicitly including immunogenicity risk 3941464748. FDA's separate 2022 draft, Sameness Evaluations in an ANDA — Active Ingredients (2022-11-08), reinforces how active-ingredient sameness is assessed in this context 38. For sponsors, the practical read is that a synthetic-versus-rDNA generic is feasible but analytically expensive, and impurity control (not just sequence identity) is where applications will be won or lost.
Clinical pharmacology expectations are being made peptide-specific
The clearest forward signal on original development is the draft guidance Clinical Pharmacology Considerations for Peptide Drug Products (2023-12-14), which addresses immunogenicity, QT assessment, renal and hepatic impairment, and mass balance for this class 313233.
Immunogenicity is the default assumption. FDA advises that most peptide drug products carry immunogenicity potential and should undergo a risk assessment considering product-, process-, subject-, and study-design factors 33. Very short peptides (fewer than 8 amino acids) are generally not expected to be immunogenic unless impurities or aggregates create risk, which ties the immunogenicity question directly back to the CMC impurity profile 33. The risk assessment should feed a multitiered clinical immunogenicity program evaluating anti-drug antibody incidence, titers, and neutralizing activity and their impact on PK, PD, efficacy, and safety, with cross-reactivity to any endogenous counterpart assessed where sequence homology exists 3233.
QT studies are generally not warranted. For peptides composed only of naturally occurring amino acids, FDA states a thorough QT study is generally not scientifically justified because such peptides have a low likelihood of direct ion-channel interaction, unless mechanistic or nonclinical/clinical data suggest proarrhythmic risk 31. This is a meaningful reduction in expected clinical pharmacology burden relative to small molecules.
ADME and organ-impairment studies are targeted, not automatic. For endogenous-type peptides, a human radiolabeled mass balance study is generally not recommended where metabolism and excretion are already understood from pharmacology and nonclinical ADME data, unless structural modifications are expected to change ADME 160. Mass balance data, when generated, are meant to guide whether dedicated renal or hepatic impairment and drug-drug interaction studies are needed, and should be timed early enough to inform those decisions 159160. Notably, FDA's general DDI guidance places peptides out of scope, directing sponsors to product- and region-specific considerations instead 183.
On CMC and characterization, FDA's expectations track biologic-style analytics: a synthetic peptide drug substance should be characterized for identity, purity, potency, and stability, including tests for related variants such as deamidated, oxidized, and aggregated forms, amino acid substitutions or adducts, and process-related contaminants 49.
What this signals for regulatory strategy
Taken together, the recent record points to a stable and increasingly articulated path:
- The NDA is the workhorse for original peptides, and the full expedited toolkit (priority review, fast track, orphan, priority review vouchers) is in reach, as Terlivaz and Mounjaro demonstrate 11011111782104.
- Peptides are regulated as chemistry with biologic-grade risk controls. Immunogenicity and impurity/aggregate control are central review issues, and the two are explicitly linked: impurity profiles drive immunogenicity risk in both the ANDA sameness framework and the clinical pharmacology draft 464733.
- Some clinical pharmacology burden is genuinely lighter. The presumption against a dedicated QT study and against automatic mass balance and organ-impairment studies for naturally-occurring-amino-acid peptides can compress the clinical pharmacology package if justified 31160.
- A generic route exists but is narrow and analytics-heavy. The 505(j) pathway is defined for five named rDNA-origin peptides and turns on exhaustive physicochemical, structural, biological, and impurity comparison to the RLD 424147.
The guidance base is still maturing: the two most peptide-specific documents (clinical pharmacology considerations and ANDA sameness evaluations) remain in draft 5153, and there is no single consolidated peptide-therapeutics nonclinical guidance, with expectations instead drawn from class-specific documents such as the GnRH analogue guidance for prostate cancer 5536. Sponsors should therefore expect the framework to keep tightening, and should confirm class-specific immunogenicity, impurity, and clinical pharmacology expectations directly with the review division early in development.